{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:24:27Z","timestamp":1769117067709,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WU21Q0"],"award-info":[{"award-number":["WU21Q0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"NICHD","doi-asserted-by":"publisher","award":["T32HD044355"],"award-info":[{"award-number":["T32HD044355"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01AR078793"],"award-info":[{"award-number":["R01AR078793"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bone.2023.116778","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:54:59Z","timestamp":1682110499000},"page":"116778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Asfotase alfa improved skeletal mineralization and fracture healing in a child with MCAHS"],"prefix":"10.1016","volume":"172","author":[{"given":"Min","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malinda","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-0936","authenticated-orcid":false,"given":"Janet L.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116778_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33176\/AACB-19-00031","article-title":"Hypophosphatasia: biological and clinical aspects, avenues for therapy","volume":"41","year":"2020","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.bone.2023.116778_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.573727","article-title":"Plasma inorganic pyrophosphate deficiency links multiparity to cardiovascular disease risk","volume":"8","author":"Veiga-Lopez","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bone.2023.116778_bb0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1359\/jbmr.071213","article-title":"Enzyme replacement therapy for murine hypophosphatasia","volume":"23","author":"Mill\u00e1n","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116778_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-020-01401-z","article-title":"The glycosylphosphatidylinositol biosynthesis pathway in human diseases","volume":"15","author":"Wu","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.bone.2023.116778_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2183\/pjab.90.130","article-title":"Biosynthesis and deficiencies of glycosylphosphatidylinositol","volume":"90","author":"Kinoshita","year":"2014","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"10.1016\/j.bone.2023.116778_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104668","article-title":"Rare multiple congenital anomalies-hypotonia-seizures syndrome type 1 (MCAHS1) - the clinical and molecular summary","volume":"66","author":"Bukowska-Olech","year":"2023","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.bone.2023.116778_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.a.37369","article-title":"Genotype-phenotype correlation of congenital anomalies in multiple congenital anomalies hypotonia seizures syndrome (MCAHS1)\/PIGN-related epilepsy","volume":"170A","author":"Fleming","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2023.116778_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J. Trop. Pediatr."},{"key":"10.1016\/j.bone.2023.116778_bb0045","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/jbmr.473","article-title":"Optimal monitoring time interval between DXA measures in children","volume":"26","author":"Shepherd","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116778_bb0050","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","article-title":"Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study","volume":"96","author":"Zemel","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116778_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115413","article-title":"Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: a pooled post hoc analysis of asfotase alfa clinical trial data","volume":"137","author":"Simmons","year":"2020","journal-title":"Bone"},{"issue":"2014","key":"10.1016\/j.bone.2023.116778_bb0060","first-page":"219","article-title":"Pediatric position development conference: executive summary and reflections","volume":"17","author":"Gordon","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2023.116778_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.gim.2022.09.007","article-title":"Biallelic variants in PIGN cause Fryns syndrome, multiple congenital anomalies-hypotonia-seizures syndrome, and neurologic phenotypes: a genotype\u2013phenotype correlation study","volume":"25","author":"Loong","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.bone.2023.116778_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1012816","article-title":"Emerging therapies for the treatment of rare pediatric bone disorders","volume":"10","author":"Thrailkill","year":"2022","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.bone.2023.116778_bb0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116778_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115794","article-title":"Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia","volume":"143","author":"St\u00fcrznickel","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116778_bb0085","series-title":"Asfotase Alfa (Strensiq) COST COMPARISON. [Internet]","year":"2017"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:06:51Z","timestamp":1757614011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":17,"alternative-id":["S8756328223001114"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116778","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asfotase alfa improved skeletal mineralization and fracture healing in a child with MCAHS","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116778"}}